Allergan Aesthetics, an AbbVie company, announced European Commission approval for its product Boey (trenibotulinumtoxinE) to treat moderate to severe lines between the eyebrows. This expands the product's market reach across 30 European Economic Area countries, following its earlier approval in Canada.
Allergan Aesthetics, a subsidiary of AbbVie, received European Commission approval for its aesthetic product Boey (trenibotulinumtoxinE) for the treatment of glabellar lines. This approval is significant as it opens up the market across 30 European Economic Area countries, adding to its prior approval in Canada. For AbbVie, this represents a positive development, expanding its product portfolio and potential revenue streams in the aesthetics market. While not a blockbuster drug approval, it contributes to the company's growth in a competitive segment. Traders might see this as a minor positive catalyst, reinforcing AbbVie's position in the aesthetics space, with long-term implications for market share and revenue growth in this specific therapeutic area.